Iradimed Co (IRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iradimed Co (IRMD) has a cash flow conversion efficiency ratio of 0.084x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.29 Million) by net assets ($98.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Iradimed Co (IRMD) balance sheet quality index to measure how much of total assets are equity-financed.
Iradimed Co - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Iradimed Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IRMD operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Iradimed Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iradimed Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Gas Group Co Ltd
SHG:603053
|
-0.008x |
|
RLJ Lodging Trust
NYSE:RLJ
|
0.029x |
|
Avanos Medical Inc
NYSE:AVNS
|
-0.016x |
|
Corbion NV
AS:CRBN
|
0.155x |
|
Lufax Holding Ltd
NYSE:LU
|
0.022x |
|
SYoung Group Co Ltd
SHE:300740
|
0.010x |
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
0.047x |
|
Preferred Bank
NASDAQ:PFBC
|
0.059x |
Annual Cash Flow Conversion Efficiency for Iradimed Co (2012–2025)
The table below shows the annual cash flow conversion efficiency of Iradimed Co from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see IRMD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $94.62 Million | $24.95 Million | 0.264x | -10.67% |
| 2024-12-31 | $86.82 Million | $25.62 Million | 0.295x | +56.55% |
| 2023-12-31 | $71.42 Million | $13.47 Million | 0.189x | +38.31% |
| 2022-12-31 | $73.67 Million | $10.04 Million | 0.136x | -12.61% |
| 2021-12-31 | $72.17 Million | $11.26 Million | 0.156x | +64.59% |
| 2020-12-31 | $61.38 Million | $5.82 Million | 0.095x | -48.58% |
| 2019-12-31 | $55.52 Million | $10.23 Million | 0.184x | +4.80% |
| 2018-12-31 | $41.95 Million | $7.38 Million | 0.176x | +69.52% |
| 2017-12-31 | $32.93 Million | $3.42 Million | 0.104x | -64.83% |
| 2016-12-31 | $31.89 Million | $9.41 Million | 0.295x | +23.14% |
| 2015-12-31 | $31.93 Million | $7.65 Million | 0.240x | +93.53% |
| 2014-12-31 | $20.89 Million | $2.59 Million | 0.124x | -54.48% |
| 2013-12-31 | $5.42 Million | $1.47 Million | 0.272x | -41.98% |
| 2012-12-31 | $3.22 Million | $1.51 Million | 0.469x | -- |
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs moni… Read more